The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

Inclusion Criteria

• •1. Age: 18 to 80 years old, both male and female are acceptable.
• •2. The imaging or pathological diagnosis is hepatocellular carcinoma;
• •3. It is planned to carry out standard treatment for liver cancer, specifically including lenvatinib + tislelizumab or lenvatinib + pembrolizumab or atezolizumab + bevacizumab.
• •4. ECOG score: 0 to 2 points;
• •5. Expected survival period ≥12 weeks;
• •6. Baseline blood cell count tests and blood biochemistry must meet the following standards:
• •White blood cell count ≥3.0×10\^9/L; Hemoglobin ≥90 g/L; The absolute neutrophil count is ≥1.5×10\^9/L; Platelet count ≥100×10\^9/L; Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal (ULN). Total bilirubin ≤ twice ULN; Serum creatinine ≤ 1.5 times ULN; Albumin ≥30 g/L;
• •7. The subjects voluntarily joined this study, signed the informed consent form, had good compliance and cooperated with the follow-up.